Cargando…
High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery
The discovery of new therapeutic options against Trypanosoma cruzi, the causative agent of Chagas disease, stands as a fundamental need. Currently, there are only two drugs available to treat this neglected disease, which represents a major public health problem in Latin America. Both available ther...
Autores principales: | Alonso-Padilla, Julio, Rodríguez, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256210/ https://www.ncbi.nlm.nih.gov/pubmed/25474364 http://dx.doi.org/10.1371/journal.pntd.0003259 |
Ejemplares similares
-
Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
por: Andriani, Grasiella, et al.
Publicado: (2011) -
Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds
por: Martinez-Peinado, Nieves, et al.
Publicado: (2021) -
In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds
por: Canavaci, Adriana M. C., et al.
Publicado: (2010) -
Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity
por: Martinez-Peinado, Nieves, et al.
Publicado: (2020) -
Correction: Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
Publicado: (2014)